Resources & Guides
Educational content about GLP-1 medications, pharmacokinetics, and optimizing your treatment journey.
GLP-1 Medication Hubs
Comprehensive guides for each GLP-1 medication—dosing protocols, clinical trial data, microdosing strategies, and our free calculators.
Semaglutide Guide
Ozempic & Wegovy: GLP-1 receptor agonist. ~15% weight loss, 7-day half-life. FDA-approved for diabetes and weight management.
Tirzepatide Guide
Mounjaro & Zepbound: Dual GLP-1/GIP agonist. ~21% weight loss, 5-day half-life. The first dual-agonist approved by FDA.
Retatrutide Guide
Triple GLP-1/GIP/Glucagon agonist. ~24% weight loss in trials, 6-day half-life. Expected FDA approval 2027.
Educational Content
Retatrutide Phase 3 Weight Loss Results: TRIUMPH Data
articleA dose-by-dose breakdown of retatrutide phase 3 weight loss results from the TRIUMPH program: TRIUMPH-1 (28.3% at 80 weeks), the 104-week extension (30.3%), TRIUMPH-4 (28.7%), safety data, and what investigational status means for access.
Retatrutide TRIUMPH-1 Cardiometabolic Outcomes Explained
articleThe TRIUMPH-1 secondary dataset presented at ADA 2026 goes beyond weight loss. Triglycerides fell 41.0%, non-HDL cholesterol 24.2%, systolic blood pressure 12.3 mmHg, and nested substudies showed up to 73.1% less knee pain and up to 60.6% less sleep apnea on retatrutide 12mg.